Pharmaceutical and biological industry 32 stocks on the list of 100 yuan shares, accounting for 25.20%

According to the Securities Times data treasure statistics show that as of the close of September 21, the stock price of the two cities more than 100 yuan has 127, to Shenwan first-class industry classification, the more concentrated industries are pharmaceutical biology, electronics, computers and so on, of which, the pharmaceutical biology industry has 32 stocks on the list, accounting for 25.20% of the total number of 100 yuan shares.
In the pharmaceutical and biological industry stocks, the stock price of more than 300 yuan has three, respectively, Kanghua Bio, Changchun Gaoxin, Meirui Medical, the stock price between 200 to 300 yuan there are 7, including Concino, Cardiel Medical, Kailaiying, Chipo , etc. , the stock price between 100 yuan to 200 yuan there are 22, involving General Medical, Wantai Bio, Kantai Bio and so on.
pharmaceutical and biological industry share prices of more than 100 yuan, the closing price is the top Kanghua Bio, 21 daily closed at 536.70 yuan, down 1.70%, followed by Changchun Gaoxin, Mei Rui Medical, the new closing price of 365.81 yuan, 319.55 yuan.
on the evening of September 17th, Kanghua Bio released its forecast for the first three quarters of 2020, which is expected to achieve net profit attributable to shareholders of listed companies of RMB325 million to RMB355 million, up 267.37% yoY - 301.28%.
explained that the big increase in earnings was due to improved corporate fundamentals.
January-September Kanghua biological products freeze-dried human rabies vaccine (human double body cells) due to market demand and other factors, production and sales, to achieve high-speed growth.
, the company's management efficiency improved, the scale effect gradually appeared.
the results of the good news, Kanghua Bio's share price began to rise, 18 opened 10.98 percent higher, leading the bio-vaccine stocks.
, the company has been riding the spring breeze of the bio-vaccine concept since it went public on June 16 this year.
share price from 70.37 yuan / share at one point rushed to 996 yuan / share, close to the 1,000 yuan share mark.
shares began to fall after the market peaked on August 4th.
industry believes that Kanghua Bio in the first three quarters of the net profit caused by the surge in the share price, is the price repair performance after the recent sharp fall in the share price, the impact on the late trend of the enterprise is limited.
as a secondary new stock of Kanghua Bio, return to the previous rally still need to look at the follow-up core technology development and breakthrough, the sustainability of performance growth is still the key.
It is understood that Kanghua Bio was established in 2004, the main business includes the prevention of biological products production, sales, research, development and technical services, the existing products of secondary cell rabies vaccine and ACYW135 group meningococcal polysaccharide vaccine.
And from the ups and downs, among the 32 stocks, Yurui Technology led the way, up 5.87 percent, Tongze Medical rose 2.79 percent, Tianyu shares rose 2.67 percent, Yifeng Pharmacy rose 2.02 percent, and Sussao Biology, New Industries, Xingqi Eye Medicine, Zhifei Bio and Sanxiang Bio rose 1.94%, 1.70%, 1.13%, 0.15% and 0.47%, respectively.
Technology listed on September 18th, issuing 18.2 million shares at an issue price of 119.6 yuan, raising a total of 2.177 billion yuan.
Technology opened at 170.2 yuan and closed at 160.1 yuan.
closing price, the market value of the company is $11.6 billion.
's main business for digital X-ray detector research and development, production, sales and services, products are widely used in medical diagnosis and treatment, industrial non-destructive testing, security inspection and other fields.
recent years, the company's performance showed a growth trend.
2017, 2018 and 2019 revenues were RMB356 million, RMB439 million and RMB546 million, respectively, with net profits of RMB54.45 million, RMB59.32 million and RMB95.318 million, according to the 2017 prospecto.
the first half of 2020, the company achieved revenue of 385 million yuan, up 91.67 percent year-on-year, and a net profit attributable to shareholders of the parent company of 109.5 million yuan.
expects operating income to be RMB525 million to RMB585 million in the January-September 2020 period, up 67% to 87% YoY, and net profit attributable to shareholders of the parent company of RMB135 million to RMB160 million.